Royalty Pharma Plc Cl A RPRX

$57.16 -0.47 (-0.82%)

Valuation

Market cap
32,867,056,000
Revenue TTM
$2,378,190,000
Net income TTM
$770,950,000
PE ratio
10.98
Forward PE
10.83
Profit margin
32.42%
Debt to equity
0.92

Trading

Volume
2,229,400
Avg volume
2,928,086
Day's range
$56.96 – $57.91
Shares out
575,001,000
Stochastic %K
10%
Beta
0.42
Analysts
Strong Sell
Price target
$65.71

Price

Company profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has...

Show more

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
212 883 0200
Website
https://www.royaltypharma.com
Address
110 East 59th Street, New York, United States

Latest news